From AGM presentation 8/11/2023
Phase I/II Clinical Trial – Treatment of Burn Wound Infections
• Stage 1 Complete
• Patients treated with R327 showed good indications of safety and tolerability
• No serious adverse events reported among patients
• Clinical investigators are preparing a new protocol of next stage
• Stage 2 clinical trial expected to be a randomised ‘head-to-head’ in patients with infected
burn wounds, where R327G treatment is compared to existing treatment standard of care.
Burns wound trial seems to have gone very quiet with no mention in the quarterly report 30/1/2024
I requested information on the Phase 1 readout (expected 4th quarter 2023) last week and so far no reply.
Does anyone have information on the Burn wound trial stage I and proposed stage II ?
From AGM presentation 8/11/2023 Phase I/II Clinical Trial –...
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
62.0¢ |
Change
-0.030(4.62%) |
Mkt cap ! $126.4M | |||
| Open | High | Low | Value | Volume |
| 65.0¢ | 65.5¢ | 61.5¢ | $78.93K | 125.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9703 | 61.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 64.0¢ | 50000 | 1 |
View Market Depth
| Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
64.0¢ |
Change
-0.030 ( 1.54 %) |
||||
| Open | High | Low | Volume | ||
| 65.5¢ | 65.5¢ | 64.0¢ | 4035 | ||
| Last updated 14.23pm 14/05/2024 ? | |||||
| RCE (ASX) Chart |